Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Current Deferred Revenue (2016 - 2024)

vTv Therapeutics' Current Deferred Revenue history spans 10 years, with the latest figure at $18.7 million for Q4 2024.

  • For Q4 2024, Current Deferred Revenue rose 109717.65% year-over-year to $18.7 million; the TTM value through Dec 2024 reached $18.7 million, up 109717.65%, while the annual FY2024 figure was $18.7 million, 109717.65% up from the prior year.
  • Current Deferred Revenue for Q4 2024 was $18.7 million at vTv Therapeutics, up from $17000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $18.7 million in Q2 2022 and bottomed at $17000.0 in Q4 2022.
  • The 5-year median for Current Deferred Revenue is $35000.0 (2021), against an average of $5.6 million.
  • The largest YoY upside for Current Deferred Revenue was 109717.65% in 2024 against a maximum downside of 99.91% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $31000.0 in 2020, then rose by 12.9% to $35000.0 in 2021, then crashed by 51.43% to $17000.0 in 2022, then changed by 0.0% to $17000.0 in 2023, then soared by 109717.65% to $18.7 million in 2024.
  • Per Business Quant, the three most recent readings for VTVT's Current Deferred Revenue are $18.7 million (Q4 2024), $17000.0 (Q3 2024), and $17000.0 (Q2 2024).